1. Home
  2. CSQ vs VERA Comparison

CSQ vs VERA Comparison

Compare CSQ & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Strategic Total Return

CSQ

Calamos Strategic Total Return

HOLD

Current Price

$20.97

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$34.27

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSQ
VERA
Founded
2003
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.0B
IPO Year
2004
2021

Fundamental Metrics

Financial Performance
Metric
CSQ
VERA
Price
$20.97
$34.27
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$81.30
AVG Volume (30 Days)
149.9K
2.4M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
7.53%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$472.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.41
$23.05
52 Week High
$21.17
$56.05

Technical Indicators

Market Signals
Indicator
CSQ
VERA
Relative Strength Index (RSI) 55.79 50.23
Support Level $20.49 $33.43
Resistance Level $21.16 $36.89
Average True Range (ATR) 0.25 1.97
MACD -0.03 -0.05
Stochastic Oscillator 80.17 48.74

Price Performance

Historical Comparison
CSQ
VERA

About CSQ Calamos Strategic Total Return

Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: